The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis

Article English OPEN
Aladul, M; Fitzpatrick, RW; Chapman, SR;

Background:\ud The approval of new biosimilars of infliximab, etanercept and adalimumab by the European Medicines Agency is expected to produce further cost savings to the healthcare system budget. \ud \ud Objectives:\ud This study aimed to estimate the budget impact of... View more
Share - Bookmark